Mexiletine and magnesium independently, but not combined, protect against permanent focal cerebral ischemia in Wistar rats

Journal of Neuroscience Research

Volumn 58, Issue 3, 1999, Pages 442-448

  Lee, E Jian ^a   Ayoub, Issam A ^c   Harris, Frederick B ^c   Hassan, Mahmood ^c   Ogilvy, Christopher S ^c   Maynard, Kenneth I ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NONE

Author keywords

Calcium channel blocker; Metabolic inhibition; Neuroprotection; Sodium channel blocker; Stroke

Indexed keywords

MAGNESIUM; MEXILETINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFECT; ENERGY CONSUMPTION; IMAGE ANALYSIS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN ISCHEMIA; CEREBRAL INFARCTION; DRUG ADMINISTRATION SCHEDULE; MAGNESIUM; MALE; MEXILETINE; MIDDLE CEREBRAL ARTERY; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 0033231438     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19991101)58:3<442::AID-JNR10>3.0.CO;2-4     Document Type: Article

References (35)

1. Ames A III, Maynard KI, Kaplan S. 1995. Protection against CNS ischemia by temporary interruption of function-related processes of neurons. J Cereb Blood Flow Metab 15:433-439.
2. Ayoub IA, Lee EJ, Ogilvy CS, Beal MF, Maynard KI. 1999. Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neurosci Lett 259:21-24.
3. Barinaga M. 1996. Finding new drugs to treat stroke. Science 272:664-666.
4. Bederson JB, Pitts LH, German SM, Nishimura MC, Davis RL. 1986a. Evaluation of 2, 3, 5-Triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17:1304-1308.
5. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL. 1986b. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17:472-476.
6. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. 1996. Middle cerebral artery occlusion in the rat by intraluminal suture: neurological and pathological evaluation of an improved model. Stroke 27:1616-1623.
7. Brown CM, Calder C, Linton C, Small C, Kenny BA, Spedding M, Patmore L. 1995. Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia. Br J Pharmacol 115:1425-1432.
8. + current? J Neurophysiol 74:934-941.
9. Chen J, Graham SH, Simon RP. 1995. A comparison of the effects of a sodium channel blocker and an NMDA antagonist upon extracellular glutamate in rat focal cerebral ischemia. Brain Res 699:121-124.
10. Fisher M. 1997. Characterizing the target of acute stroke therapy. Stroke 28:866-872.
11. Gomez MN. 1998. Magnesium and cardiovascular disease. Anesthesiology 89:222-240.
12. Granam SH, Chen J, Lan J, Leach MJ, Simon RP. 1994. Neuroprotective effects of a use-dependent blocker of voltage-dependent sodium channels, BW619C89, in rat middle cerebral artery occlusion. J Pharmacol Exp Ther 269:854-859.
13. Grotta J. 1994. The current status of neuronal protective therapy: why all neuronal protective drugs worked in animals but none so far in stroke patients? Cerebrovasc Dis 4:115-120.
14. Hammarstrom AK, Gage PW. 1998. Inhibition of oxidative metabolism increases persistent sodium current in rat CA1 hippocampal neurons. J Physiol (Lond) 510:735-741.
15. Johansson BW, Stavenow L, Hanson A. 1984. Long-term clinical experience with mexiletine. Am Heart J 107:1099-1102.
16. Kempski OS. 1994. Neuroprotection:Models and basic principles. Anaesthesist 43:S25-33.
17. Longa EZ, Weinstein PR, Carlson S, Cummins R. 1989. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-91.
18. 2+ of NMDA responses in spinal cord neurones. Nature 309:261-263.
19. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. 1996. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 85:117-124.
20. Maynard KI, Kawamata T, Ogilvy CS, Perez F, Arango PM, Ames A III. 1998a. Avoiding stroke during cerebral arterial occlusion by temporarily blocking neuronal functions in the rabbit. J Stroke Cerebrovasc Dis 7:287-295.
21. Maynard KI, Quiñones-Hinojosa A, Ogilvy CS. 1998b. Magnesium plus mexiletine inhibit energy usage and protect retinas against ischemia. NeuroReport 9:4141-4144.
22. Pringle AK, Iannotti F, Wilde GJ, Chad JE, Seeley PJ, Sundstrom LE. 1997. Neuroprotection by both NMDA and non-NMDA receptor antagonists in in vitro ischemia. Brain Res 755:35-46.
23. Ren JM, Finklestein SP. 1997. Time window of infarct reduction by intravenous basic fibroblast growth factor in focal cerebral ischemia. Eur J Pharmacol 327:11-16.
24. Shanks RG. 1984. Hemodynamic effects of mexiletine. Am Heart J 107:1065-1071.
25. Siesjö BK. 1992. Pathophysiology and treatment of focal cerebral ischemia. part I: pathophysiology. J Neurosurg 77:169-184.
26. Small DL, Buchan AM. 1996. Mechanism of cerebral ischemia: intracellular cascade and therapeutic intervention. J Cardiovascular Vas Anesth 10:139-146.
27. Stys PK. 1998. Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J Cereb Blood Flow Metab 18:2-25.
28. Stys PK, Lesiuk H. 1996. Correlation between electrophysiological effects of mexiletine and ischemic protection in central nervous system white matter. Neuroscience 71:27-36.
29. Stys PK, Lopachin RM. 1998. Mechanism of calcium and sodium fluxes in anoxic myelinated central nervous system axons. Neuroscience 82:21-32.
30. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. 1990. A semiautomated method for measuring brain infarct volumes. J Cereb Blood Flow Metab 10:290-293.
31. ++ protect against irreversible damage during CNS ischemia. Stroke 15:695-698.
32. van der Hel WS, Van den Bergh WM, Nicolay K, Tulleken KAF, Dijkhuizen RM. 1998. Suppression of cortical spreading depressions after magnesium treatment in the rat. NeuroReport 9:2179-2182.
33. Woosley RL, Wang T, Stone W, Siddoway L, Thompson K, Duff HJ, Cerskus I, Roden D. 1984. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. Am Heart J 107:1058-1065.
34. Xie Y, Dengler K, Zacharias E, Wilffert B, Tegtmeier F. 1994. Effects of the sodium channel blocker tetrodotoxin (TTX) on cellular ion homeostasis in rat brain subjected to complete ischemia. Brain Res 652:216-224.
35. Zager EL, Ames A III .1988. Reduction of cellular energy requirements: screening for agents that may protect against CNS ischemia. J Neurosurg 69:568-579.